Aminoazabenzimidazoles, a Novel Class of Orally Active Antimalarial Agents

Journal of Medicinal Chemistry

Volumn 57, Issue 13, 2014, Pages 5702-5713

  Hameed P, Shahul ^a   Chinnapattu, Murugan ^a   Shanbag, Gajanan ^a   Manjrekar, Praveena ^a   Koushik, Krishna ^a   Raichurkar, Anandkumar ^a   Patil, Vikas ^a   Jatheendranath, Sandesh ^a   Rudrapatna, Suresh S ^a   Barde, Shubhada P ^a   Rautela, Nikhil ^a   Awasthy, Disha ^a   Morayya, Sapna ^a   Narayan, Chandan ^a   Kavanagh, Stefan ^a   Saralaya, Ramanatha ^a   Bharath, Sowmya ^a   Viswanath, Pavithra ^a   Mukherjee, Kakoli ^a   Bandodkar, Balachandra ^a   Srivastava, Abhishek ^a   Panduga, Vijender ^a   Reddy, Jitender ^a   Prabhakar, K R ^a   Sinha, Achyut ^a   Jiménez Díaz, María Belén ^d   Martínez, María Santos ^d   Angulo Barturen, Iñigo ^d   Ferrer, Santiago ^d   Sanz, Laura María ^d   Gamo, Francisco Javier ^d   Duffy, Sandra ^c   Avery, Vicky M ^c   Magistrado, Pamela A ^e   Lukens, Amanda K ^e   Wirth, Dyann F ^e   Waterson, David ^b   Balasubramanian, V ^a   Iyer, Pravin S ^a   Narayanan, Shridhar ^a   Hosagrahara, Vinayak ^a   Sambandamurthy, Vasan K ^a   Ramachandran, Sreekanth ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b International Center Cointrin   (Switzerland)

^c GRIFFITH UNIVERSITY   (Australia)

^d GLAXOSMITHKLINE   (Spain)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 2 (2 NITRO 1H IMIDAZOL 1 YL)ETHANOL; 1 (2,4 DICHLOROPHENYL) 2 (2 NITRO 1H IMIDAZOL 1 YL)ETHANONE; 2 (2 AMINO 1H BENZO[D]IMIDAZOL 1 YL) 1 (2,4 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 1H IMIDAZOL 1 YL) 1 (2,3 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 1H IMIDAZOL 1 YL) 1 (2,4 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 1H IMIDAZOL 1 YL) 1 (4 CHLORO 2 FLUOROPHENYL)ETHAN 1 OL; 2 (2 AMINO 1H IMIDAZOL 1 YL) 1 (4 CHLORO 2 METHYLPHENYL)ETHAN 1 OL; 2 (2 AMINO 1H IMIDAZO[4,5 C]PYRIDIN 1 YL) 1 (2,4 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 3H IMIDAZO[4,5 B]PYRIDIN 3 YL) 1 (2,3 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 4 CYCLOPROPYL 1H IMIDAZOL 1 YL) 1 (2,4 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 4 METHYL 1H IMIDAZOL 1 YL) 1 (2,4 DICHLOROPHENYL)ETHANOL; 2 (2 AMINO 4,5 DIMETHYL 1H IMIDAZOL 1 YL) 1 (2,4 DICHLOROPHENYL)ETHAN 1 OL; 2 (2 AMINO 6 CHLORO 1H BENZO[D]IMIDAZOL 1 YL) 1 (2,3 DICHLOROPHENYL)ETHANOL; 2 AMINO 1 [2 (2,3 DICHLOROPHENYL) 2 HYDROXYETHYL] 1H BENZO[D]IMIDAZOLE 6 CARBONITRILE; 2 [2 AMINO 4 (4 FLUOROPHENYL) 1H IMIDAZOL 1 YL] 1 [2 CHLORO 4 (TRIFLUOROMETHYL)PHENYL]ETHANOL; 2 [2 AMINO 5 (4 METHYLPIPERAZIN 1 YL) 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] 1 [2 CHLORO 4 (TRIFLUOROMETHYL)PHENYL]ETHAN 1 OL; 2 [2 AMINO 5 (4 METHYLPIPERAZIN 1 YL) 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] 1 [2 CHLORO 4 (TRIFLUOROMETHYL)PHENYL]ETHAN 1 ONE; 2 [2 AMINO 5 [(2,2,2 TRIFLUOROETHYL)AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] 1 (2,4 DICHLOROPHENYL)ETHANOL; 2 [2 AMINO 6 (METHYLSULFONYL) 1H BENZO[D]IMIDAZOL 1 YL] 1 (2,3 DICHLOROPHENYL)ETHANOL; 2 [2 AMINO 6 (TRIFLUOROMETHYL) 1H BENZO[D]IMIDAZOL 1 YL] 1 [2 CHLORO 4 (TRIFLUOROMETHYL)PHENYL]ETHANOL; 5 (4 METHYLPIPERAZIN 1 YL) 3H IMIDAZO[4,5 B]PYRIDIN 2 AMINE; 6 (4 METHYLPIPERAZIN 1 YL) 3 NITROPYRIDIN 2 AMINE; 6 (4 METHYLPIPERAZIN 1 YL)PYRIDINE 2,3 DIAMINE; AMINOAZABENZIMIDAZOLE DERIVATIVE; ANTIMALARIAL AGENT; ARTESUNATE; BENZIMIDAZOLE DERIVATIVE; CHLOROQUINE; PYRIMETHAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; LIPOPHILICITY; MALARIA FALCIPARUM; MALE; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL SURVIVAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; MICE; PLASMODIUM FALCIPARUM; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904296361     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500535j     Document Type: Article

References (27)

1. WHO. World Malaria Report 2013. http://www.who.int/malaria/publications/ world-malaria-report-2013/en/, accessed on January 10, 2014.
2. Ariey, F.; Witkowski, B.; Amaratunga, C.; Beghain, J.; Langlois, A. C.; Khim, N.; Kim, S.; Duru, V.; Bouchier, C.; Ma, L.; Lim, P.; Leang, R.; Duong, S.; Sreng, S.; Suon, S.; Chuor, C. M.; Bout, D. M.; Ménard, S.; Rogers, W. O.; Genton, B.; Fandeur, T.; Miotto, O.; Ringwald, P.; Le Bras, J.; Berry, A.; Barale, J. C.; Fairhurst, R. M.; Benoit-Vical, F.; Mercereau-Puijalon, O.; Ménard, D. A molecular marker of artemisinin resistant Plasmodium falciparum malaria Nature 2014, 505, 50-55
3. Burrows, J. N.; Burlot, E.; Campo, B.; Cherbuin, S.; Jeanneret, S.; Leroy, D.; Spangenberg, T.; Waterson, D.; Wells, T. N.; Willis, P. Antimalarial drug discovery-The path towards eradication Parasitology 2014, 141, 128-139
4. Lee, J. A.; Uhlik, M. T.; Moxham, C. M.; Tomandl, D.; Sall, D. J. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy J. Med. Chem. 2012, 55, 4527-4538
5. Canavaci, A. M.; Bustamante, J. M.; Padilla, A. M.; Perez Brandan, C. M.; Simpson, L. J.; Xu, D.; Boehlke, C. L.; Tarleton, R. L. In vitro and in vivo high-throughput assays for the testing of anti- Trypanosoma cruzi compounds PLoS Neglected Trop. Dis. 2010, 4, e740
6. Sykes, M. L.; Baell, J. B.; Kaiser, M.; Chatelain, E.; Moawad, S. R.; Ganame, D.; Ioset, J. R.; Avery, V. M. Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign PLoS Neglected Trop. Dis. 2012, 6, e1896
7. Jones, A. J.; Avery, V. M. Whole-organism high-throughput screening against Trypanosoma brucei brucei Expert Opin. Drug Discovery 2013, 8, 495-507
8. Mackey, Z. B.; Baca, A. M.; Mallari, J. P.; Apsel, B.; Shelat, A.; Hansell, E. J.; Chiang, P. K.; Wolff, B.; Guy, K. R.; Williams, J.; McKerrow, J. H. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei Chem. Biol. Drug Des. 2006, 67, 355-363
9. Murugesan, D.; Mital, A.; Kaiser, M.; Shackleford, D. M.; Morizzi, J.; Katneni, K.; Campbell, M.; Hudson, A.; Charman, S. A.; Yeates, C.; Gilbert, I. H. Discovery and structure-activity relationships of pyrrolone antimalarials J. Med. Chem. 2013, 56, 2975-2990
10. Rottmann, M.; McNamara, C.; Yeung, B. K.; Lee, M. C.; Zou, B.; Russell, B.; Seitz, P.; Plouffe, D. M.; Dharia, N. V.; Tan, J.; Cohen, S. B.; Spencer, K. R.; González-Páez, G. E.; Lakshminarayana, S. B.; Goh, A.; Suwanarusk, R.; Jegla, T.; Schmitt, E. K.; Beck, H. P.; Brun, R.; Nosten, F.; Renia, L.; Dartois, V.; eller, T. H.; Fidock, D. A.; Winzeler, E. A.; Diagana, T. T. Spiroindolones, a potent compound class for the treatment of malaria Science 2010, 329, 1175-1180
11. Guiguemde, W. A.; Shelat, A. A.; Garcia-Bustos, J. F.; Diagana, T. T.; Gamo, F. J.; Guy, R. K. Global phenotypic screening for antimalarials Chem. Biol. 2012, 19, 116-129
12. Sykes, M. L.; Avery, V. M. Approaches to protozoan drug discovery: phenotypic screening J. Med. Chem. 2012, 56, 7727-7740
13. Duffy, S.; Avery, V. M. Development and optimization of a novel anti-malarial imaging assay validated for high throughput screening Am. J. Trop. Med. Hyg. 2012, 86, 84-92
14. Eakin, A. E.; Green, O.; Hales, N.; Walkup, G. K.; Bist, S.; Singh, A.; Mullen, G.; Bryant, J.; Embrey, K.; Gao, N.; Breeze, A.; Timms, D.; Andrews, B.; Uria-Nickelsen, M.; Demeritt, J.; Loch, J. T., 3rd.; Hull, K.; Blodgett, A.; Illingworth, R. N.; Prince, B.; Boriack-Sjodin, P. A.; Hauck, S.; MacPherson, L. J.; Ni, H.; Sherer, B. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents Antimicrob. Agents Chemother. 2012, 56, 1240-1246
15. Bennett, T. N.; Paguio, M.; Gligorijevic, B.; Seudieu, C.; Kosar, A. D.; Davidson, E.; Roepe, P. D. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy Antimicrob. Agents Chemother. 2004, 48, 1807-1810 (Pubitemid 38544393)
16. Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J. X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening Antimicrob. Agents Chemother. 2004, 48, 1803-1806 (Pubitemid 38544392)
17. Shirude, P. S.; Shandil, R.; Sadler, C.; Naik, M.; Hosagrahara, V.; Hameed, S.; Shinde, V.; Bathula, C.; Humnabadkar, V.; Naveen Kumar, C. N.; Reddy, J.; Panduga, V.; Sharma, S.; Ambady, A.; Hegde, N.; Whiteaker, J.; McLaughlin, R. E.; Gardner, H.; Madhavapeddi, P.; Ramachandran, V.; Kaur, P.; Narayan, A.; Guptha, S.; Awasthy, D.; Narayan, C.; Mahadevaswamy, J.; Vishwas, K. G.; Ahuja, V.; Srivastava, A.; Prabhakar, K. R.; Bharath, S.; Kale, R.; Ramaiah, M.; Roy Choudhury, N.; Sambandamurthy, V. K.; Solapure, S.; Iyer, P. S.; Narayanan, S.; Chatterji, M. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo J. Med. Chem. 2013, 56, 9701-9708
18. Chawira, A. N.; Warhurst, D. C.; Robinson, B. L.; Peters, W. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice Trans. R. Soc. Trop. Med. Hyg. 1987, 81, 554-558 (Pubitemid 17121105)
19. Angulo-Barturen, I.; Jiménez-Díaz, M. B.; Mulet, T.; Rullas, J.; Herreros, E.; Ferrer, S.; Jiménez, E.; Mendoza, A.; Regadera, J.; Rosenthal, P. J.; Bathurst, I.; Pompliano, D. L.; Gómez de las Heras, F.; Gargallo-Viola, D. A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes PLoS One 2008, 3, e2252
20. Ross, L. S.; Javier Gamo, F.; Lafuente-Monasterio, M. J.; Singh, O. M.; Rowland, P.; Wiegand, R. C.; Wirth, D. F. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth. J. Biol. Chem. DOI: 10.1074/jbc.M114.558353. Published Online: Apr 29, 2014.
21. Lukens, A. K.; Ross, L. S.; Heidebrecht, R.; Gamo, F. J.; Lafuente-Monasterioc, M. J.; Bookerd, M. L.; Hartl, D. L.; Wiegand, R. C.; Wirth, D. F. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance Proc. Natl. Acad. Sci. U.S.A. 2013, 111, 799-804
22. Flannery, E. L.; Fidock, D. A.; Winzeler, E. A. Using genetic methods to define the targets of compounds with antimalarial activity J. Med. Chem. 2013, 56, 7761-7771
23. Sanz, L. M.; Crespo, B.; De-Cózar, C.; Ding, X. C.; Llergo, J. L.; Burrows, J. N.; García-Bustos, J. F.; Gamo, F. J. Plasmodium falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action PLoS One 2012, 7, e30949
24. Le Manach, C.; Scheurer, C.; Sax, S.; Schleiferböck, S.; Cabrera, D. G.; Younis, Y.; Paquet, T.; Street, L.; Smith, P.; Ding, X. C.; Waterson, D.; Witty, M. J.; Leroy, D.; Chibale, K.; Wittlin, S. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum Malar. J. 2013, 12, 424-430
25. Delves, M. J.; Ruecker, A.; Straschil, U.; Lelièvre, J.; Marques, S.; López-Barragán, M. J.; Herreros, E.; Sinden, R. E. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs Antimicrob. Agents Chemother. 2013, 57, 3268-3274
26. Delves, M.; Plouffe, D.; Scheurer, C.; Meister, S.; Wittlin, S.; Winzeler, E. A.; Sinden, R. E.; Leroy, D. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites PLoS Med. 2012, 9, e1001169
27. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture Science 1976, 193, 673-675